PATENT CLAIM ANALYSIS

Application Number: 16105479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "231500"]

Abstract:
Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.

Claim (Index 68):
The method of  claim 59 , wherein the treating further comprises reducing the number of blasts in the bone marrow or peripheral blood of the subject, or reducing the number of myeloblasts in the bone marrow or peripheral blood of the subject, or reducing the number of sideroblasts or ringed sideroblasts in the bone marrow or peripheral blood of the subject, or increasing the concentration of normal red blood cells, normal white blood cells and/or platelets in the subject, or increasing the concentration of hemoglobin in the subject.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 96.0
- Lexical Diversity: 1.21429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15328235', '15816372', '15048389', '14783360', '14408475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7669611895963057
- 35 USC 102 Novelty (BERT): 0.6466145916006075
- Combined Prediction Score: 0.7549265297967358
- Mean Citation Score: 336.052712
- Max Citation Score: 643.62946
- Similarity Product: 562.1818609855031

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test